Multiplying the possibilities - Capstan Therapeutics
Capstan Therapeutics to Present Preclinical Data at SITC Demonstrating Rapid Anti-Primary B Cell and Anti-Tumor Activity in Mice with Proprietary Targeted Lipid Nanoparticles Delivering an Anti-CD19 CAR mRNA Construct
Capstan Therapeutics Launches with $165 Million to Deliver on the ...
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body.
Capstan Therapeutics to Present Preclinical Data on Lead In Vivo ...
SAN DIEGO, September 26, 2024 – Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using CellSeeker™, a targeted lipid nanoparticle (tLNP) technology platform, today announced it will present preclinical data on CPTX2309, Capstan’s lead in vivo CAR ...
Capstan Therapeutics Announces $175M Oversubscribed Series B …
SAN DIEGO, March 20, 2024 – Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of …
Capstan Therapeutics Presents Preclinical Data on Lead In Vivo …
2024年11月18日 · Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders.
Capstan Therapeutics to Present Preclinical Data at SITC …
SAN DIEGO, October 31, 2023 – Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery utilizing targeted lipid nanoparticles (tLNP), today announced it will present preclinical data showing rapid and robust anti-tumor and anti-primary B cell activity in ...
nanoparticles (LNP) as COVID vaccines, Capstan Therapeutics has developed a non-viral novel targeted LNP (tLNP) platform, that is purpose-built for specific delivery of therapeutic CAR in mRNA format to immune cells through functionalization with a targeting antibody.
ACR 2024: Effective Engineering of CD8+ T Cells from …
Cookies. We are using cookies to improve your website experience. You may disable them from your browser settings at any time.
Capstan Therapeutics Appoints Ramin Farzaneh-Far, M.D., as Chief ...
SAN DIEGO, JANUARY 8, 2024 – Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through mRNA delivery using targeted lipid nanoparticles (tLNP), today announced the appointment of Ramin Farzaneh-Far, M.D., as Chief Medical Officer and the promotion of Miguel Arcinas to ...
Capstan Therapeutics to Participate in Upcoming Investor …
2024年11月14日 · Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders.